Diana R. Wetmore, PhD.
Diana Wetmore is Vice President of Therapeutics Development and Director of the Innovation Support Center, and manages the portfolio of scholar projects that are supported by the Harrington Discovery Institute (HDI).
Diana is a business-oriented scientist with a successful history of assembling and guiding complex multi-disciplinary drug discovery collaborations and project teams. At HDI, her portfolio management role is critical for ensuring that the Harrington Innovator, Gund-Harrington, and ADDF-Harrington scholar drug discovery projects have access to support and guidance that will help translate their ideas to the clinic and to patients. A key component of that support is the Innovation Support Center (ISC), which Diana directs. Members of the ISC panel bring pharma expertise and know-how to the portfolio projects with a view to accelerating the development of new therapies.
Diana obtained her PhD in Biochemistry at the University of Calgary, Canada, and did her postdoctoral training at Dupont Merck Pharmaceutical Company. During her more than 20 years in the drug discovery field, she has been part of project teams that yielded multiple INDs and two approved drugs. She has a combination of experience in Pharma, Biotech, and not-for-profit settings acquired in the US and internationally.
Prior to joining Harrington Discovery Institute, Diana served as VP Alliance Management and Operations for Beryllium Discovery, a structure based drug discovery organization, as VP of Business Development and Alliance Management at Cystic Fibrosis Foundation Therapeutics (CFFT) and as Sr. Director of Project Management at Anadys Pharmaceuticals. At CFFT she was an active member of the Vertex project team that led to the two first in class disease modifying therapies Kalydeco™ and Orkambi™. Professional interests include protein structure/function relationships and ligand recognition, strategic planning and building collaborative drug discovery projects.